Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

27/06/2024 - Détachement de for dividende intermédiaire

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Chugai Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,637 JPY

Average target price

5,932 JPY

Spread / Average Target

+5.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHUGAI PHARMACEUTICAL CO., LTD	+7.62%	58.06B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+47.26%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+18.40%	247B
ROCHE HOLDING AG	+3.64%	229B
NOVARTIS AG	+12.98%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B

Other Pharmaceuticals

Delayed Japan Exchange Other stock markets 10:12:50 26/06/2024 am IST			5-day change	1st Jan Change
5,744 ^JPY	+1.90%		+11.57%	+7.62%

24/06	Japan's Nikkei ends choppy session on stronger note	RE
24/06	Japan's Nikkei squeezes out gains in choppy session	RE

Japan's Nikkei ends choppy session on stronger note	24/06	RE
Japan's Nikkei squeezes out gains in choppy session	24/06	RE
Japan's Nikkei rises on US stocks, heavyweight chip shares	11/06	RE
Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook	23/05	RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	14/05	RE
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	01/05	MT
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	25/04	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	24/04	MT
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending December 31, 2024; Provides Dividend Guidance for the Year Ending December 31, 2024	24/04	CI
Japan's Nikkei slips on caution ahead of US inflation data	10/04	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	29/03	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	27/03	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	04/03	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	26/02	MT
Nikkei extends record rally on pharma boost	26/02	RE
Nikkei hits record high as index heavyweights advance	26/02	RE
US Tech Outlook Boost Asian Stock Markets	22/02	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	01/02
Chugai Pharmaceutical’s Profit Down 13% in 2023	01/02	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024	01/02	CI
From scandal to delisting: Toshiba's long-running crisis	19/12	RE
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy	14/12	MT
Transcript : Chugai Pharmaceutical Co., Ltd. - Pre Recorded Special Call	28/11
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	27/11	MT
Chugai Pharmaceutical’s Attributable Profit down 13.9% in Fiscal due to One-Off Lump-Sum Settlement;Shares Shed over 2.6%	24/23/24	MT